Needham & Company Maintains a 'Hold' on Obagi Medical Products (OMPI); Strong Start, But Valuation Keeps Us Sidelined
Tweet Send to a FriendGet Alerts OMPI Hot Sheet
Price: $23.98 --0%
Rating Summary:
0 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 20 | New: 16
Rating Summary:
0 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 20 | New: 16
Trade OMPI Now!
Needham & Company maintains a 'Hold' on Obagi Medical Products (NASDAQ: OMPI).
Analyst, Elliot Wilbur, said, "OMPI kicked off its 2012 financials with the largest positive revenue surprise vs. consensus in over two years, even more impressive considering the company derived essentially no benefit from new physician account additions and only a modest contribution from new product introductions in the period. Despite the strong start, management stuck to its guns, reiterating prior year revenue guidance though with resumption of shipments into the Texas market (~8% of historical sales) just yesterday, we suspect top-line trends will at least track toward the higher end of current guidance range."
For an analyst ratings summary and ratings history on Obagi Medical Products click here. For more ratings news on Obagi Medical Products click here.
Shares of Obagi Medical Products closed at $12.85 yesterday, with a 52 week range of $8.61-$13.75.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Elliot Wilbur, said, "OMPI kicked off its 2012 financials with the largest positive revenue surprise vs. consensus in over two years, even more impressive considering the company derived essentially no benefit from new physician account additions and only a modest contribution from new product introductions in the period. Despite the strong start, management stuck to its guns, reiterating prior year revenue guidance though with resumption of shipments into the Texas market (~8% of historical sales) just yesterday, we suspect top-line trends will at least track toward the higher end of current guidance range."
For an analyst ratings summary and ratings history on Obagi Medical Products click here. For more ratings news on Obagi Medical Products click here.
Shares of Obagi Medical Products closed at $12.85 yesterday, with a 52 week range of $8.61-$13.75.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
- UPDATE: Michael Kors (KORS) Under-Appreciated; Canaccord Genuity Starts at Buy
- UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
